Brief: Sangamo Therapeutics Receives U.S. FDA Fast Track Designation For ST-503
02/12/2025 13:15
Dec 2 (Reuters) - Sangamo Therapeutics Inc SGMO.O: SANGAMO THERAPEUTICS RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ST-503 FOR THE TREATMENT OF SMALL FIBER NEUROPATHY SANGAMO THERAPEUTICS INC - EXPECTS TO DOSE FIRST PHASE 1/2 STAND STUDY PATIENT IN THE COMING MONTHS Source text: ID:nGNX92CZr9 Further company coverage: SGMO.O ((Reuters.Briefs@thomsonreuters.com;))